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Abstract. Objective: To study self-ad-
ministration and pharmacokinetics (PK) of 
subcutaneous (SC) belimumab in patients 
with systemic lupus erythematosus (SLE). 
Methods: Patients previously treated with be-
limumab self-administered belimumab 200 mg 
SC weekly for 8 weeks using an autoinjector. 
The primary endpoint was the proportion of 
patients able to self-administer their first and 
second dose (weeks 1 and 2) in the clinic. The 
proportion able to self-administer at weeks 4 
and 8 (clinic) and weeks 3, 5, 6, and 7 (home) 
were secondary endpoints. Belimumab PK, 
safety, and injection-site pain were assessed. 
Results: 91/95 patients completed the study 
(withdrawals: adverse events (AEs): 3; lost to 
follow-up: 1). 93% were female, and mean 
(SD) age was 44.8 (12.50) years. The majority 
(99%, 89/90; no attempt, n = 5) successfully 
self-administered belimumab SC at weeks 
1 and 2 (5 had clinic staff assistance), and 
98% (85/87) successfully self-administered at 
weeks 4 and 8. Home-administration success 
rates were high (93%, (81/87) at weeks 3, 5, 
6, and 7). Week 8 median trough concentration 
was 113 µg/mL. For patients with a ≤ 1.5-week 
interval between IV SC administration, week-1 
concentrations were higher vs. week 8 (+ 51% 
median) but within a range observed with IV 
dosing; those with a ≥ 2.5-week interval had 
median differences close to 0. AEs and serious 
AEs were low, with no deaths; pain levels were 
low and decreased with subsequent injections. 
Conclusion: Patients with SLE successfully 
self-administered belimumab SC using a novel 
autoinjector; the PK profile was stable follow-
ing a switch from IV with acceptable AE and 
pain levels. The recommended dosing interval 
between IV to SC dosing is 1 – 4 weeks.
Introduction
Systemic lupus erythematosus (SLE) is 
a chronic, autoimmune, inflammatory dis-
ease that causes considerable burden to pa-
tients and society [1]. Belimumab is a human, 
monoclonal antibody that binds to and inhib-
its the biological activity of B-lymphocyte 
stimulator (BLyS) [2]. The efficacy and safety 
of intravenous (IV) belimumab were demon-
strated in two large, randomized, multicenter, 
placebo-controlled trials, BLISS 52, and 
BLISS 76 [3, 4]. Subsequently, belimumab 
10 mg/kg IV was approved for use in adults 
with active, autoantibody-positive SLE, as 
an add-on to standard SLE therapy [5]. The 
dosing regimen for belimumab IV requires 
administration in an infusion center every 4 
weeks. Devices for subcutaneous (SC) deliv-
ery of belimumab, which are safe and easy 
to self-administer, would be a significant ad-
vance for patients with active disease.
Several SC treatments are available to treat 
rheumatoid arthritis (RA) [6, 7, 8, 9]. SC treat-
ment enabled patients with RA to continue their 
everyday routine and reduced the need to travel 
to an infusion center, a factor that resulted in 
more patients choosing a SC treatment [10]. 
There is a high level of patient acceptance with 
autoinjector devices in RA, including patients 
with severe hand disability [11]. Musculoskel-
etal and mucocutaneous manifestations, such 
as fatigue, joint pain, and swelling, are com-
mon in patients with active SLE, particularly 
in the fingers, hands, and wrists, and can im-
pact the patient’s ability to carry out day-to-day 
tasks [12, 13, 14]. As patients with SLE have 
similar therapeutic needs to patients with RA, 
autoinjector usability should be studied in these 
patients. A novel single-use autoinjector has 
been developed for SC delivery of belimumab. 
In a single-dose study of healthy volunteers, 
the autoinjector demonstrated good usability, 
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reliability, and safety following self-adminis-
tration [15]. Four weekly doses of belimumab 
200 mg SC were well tolerated in healthy vol-
unteers, and it was predicted that weekly ad-
ministration would achieve exposures compa-
rable to the approved IV dosing regimen [16]. 
As patients currently treated with belimumab 
IV may choose to switch to the SC formulation 
following regulatory approval, the pharmaco-
kinetic (PK) profile across the IV-to-SC switch 
should be examined to determine the optimum 
dosing interval.
The aims of this study were to assess the 
suitability of a novel autoinjector for self-ad-
ministration of belimumab by patients with 
active SLE under real-life conditions, change 
in PK trough concentrations when switching 
from IV to SC administration, and safety and 
tolerability of belimumab administered via 
the autoinjector.
Methods
Study design and treatment
This was an open-label, single-arm, 
multi-dose study in patients with SLE (GSK 
protocol 200339; NCT02124798). The study 
was conducted in accordance with the Dec-
laration of Helsinki 2008 [17] and approved 
by an Institutional Review Board. All pa-
tients provided written, informed consent 
prior to study enrollment. Adult patients 
(> 18 years) with active, autoantibody-pos-
itive SLE (American College of Rheuma-
tology criteria [18]) receiving belimumab 
treatment were included. Patients were eli-
gible to switch from belimumab IV or beli-
mumab SC (prefilled syringe) to belimumab 
SC (autoinjector) and could continue their 
other SLE treatments (Figure 1). Patients 
who switched from belimumab IV to belim-
umab SC (autoinjector) must have received 
belimumab IV every 4 weeks for at least 
three 4-week cycles or have completed the 
open-label phase of a phase-3 belimumab 
SC study (prefilled syringe) (GSK protocol 
BEL112341; NCT01484496) and initiated 
treatment with belimumab IV. Day 0 (first 
dose belimumab SC) was targeted to be 1 – 4 
weeks (~ 2 weeks) after the last dose of beli-
mumab IV. Patients who completed the prior 
belimumab SC study, but who did not then 
initiate treatment with belimumab IV, could 
also participate. For this switch from belim-
umab SC (prefilled syringe) to belimumab 
SC (autoinjector), the first dose administered 
Figure 1. Study design. AE = adverse events; clinic = self-administration of belimumab SC at the clinic; 
home = self-administration of belimumab SC at home; IV = intravenous; PK = blood sample taken for 
pharmacokinetic analysis prior to belimumab administration; SC = subcutaneous.
Figure 2. Autoinjector device. Registered design 
protection granted/pending. Image originally pub-
lished in Struemper et al. 2015 [15].
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using the autoinjector was scheduled up to 
16 weeks (target 1 week) after the last dose 
of belimumab SC by prefilled syringe.
Patients self-administered belimumab 
200 mg SC (1 mL) using the autoinjector 
device (Figure 2) for 8 weekly doses, alter-
nating between thigh and abdomen injection 
sites. Patients received training on the use of 
the autoinjector at screening and prior to their 
first injection (week 1). Training consisted of 
reviewing the instructions for use and per-
forming a supervised practice injection using 
a foam pad. Injections at weeks 1, 2, 4, and 8 
were performed in the clinic, and injections at 
weeks 3, 5, 6, and 7 were performed outside 
the clinic (home). Patients were supervised 
during the first injection and could receive 
support from site staff at all visits. Patients 
attended an exit visit 4 weeks after the final 
injection. At study completion, patients could 
resume or initiate treatment with belimumab 
IV (10 mg/kg every 4 weeks) 2 – 3 weeks 
after the last belimumab SC dose; IV loading 
doses were not required. The recommended 
time intervals between last IV dose and the 
first SC dose, and between last SC dose and 
restarting IV administration, were chosen 
such that the new SC or resumed IV regimens 
started close to their predicted steady-state 
trough concentrations [16].
Endpoints and assessments
The primary endpoint was the proportion 
of patients successfully able to self-admin-
ister their first and second doses (weeks 1 
and 2) in the clinic, monitored by site staff. 
The proportion of patients successfully able 
to self-administer doses in weeks 4 and 8 
(clinic) and the proportion of patients who 
recorded successful self-administration at 
home in weeks 3, 5, 6, and 7 were second-
ary endpoints. In order to assess usability 
and reliability, the rate of successful (fully 
complete) self-administered injections rela-
tive to attempted self-administered injections 
was assessed. Patients used diaries to record 
injection details (e.g., time, date, injection 
site), assess the completeness of the injec-
tion, and document their experience with the 
autoinjector. Clinic injections were assessed 
by site staff. An injection was considered 
successful if the correct injection site (ab-
domen or thigh) was used, if the device was 
correctly actuated while placed on the injec-
tion site, and if the device was held in place 
until the full dose was delivered. Patients 
were permitted a second attempt; if the sec-
ond attempt was successful, this was deemed 
an overall successful injection. Percent com-
pliance was calculated as 100 X ([number of 
injections prescribed – number of injections 
missed]/ number of injections prescribed).
Blood samples for PK analyses were tak-
en at weeks 1, 2, 4, and 8 prior to SC dosing 
and belimumab trough concentrations (Cmin) 
were assessed. According to the prespecified 
analysis plan, the difference between week-8 
and week-0 concentrations was analyzed rel-
ative to the case report form (CRF)-recorded 
time interval between the last IV and the first 
SC dose and according to body mass index 
(BMI) categories (underweight: < 18.5, nor-
mal: 18.5 to < 25, overweight: 25 to < 30 and 
obese: ≥ 30 kg/m2). Several patients received 
their first SC dose more than the targeted 4 
weeks after their last IV dose; these patients 
were not excluded from the analysis. After 
database lock and generation of Figure 6 and 
the associated statistical summary, 3 of the 
95 patients in the PK population were deter-
mined to have shorter time intervals between 
the last IV and first SC dose than recorded in 
the CRF (1 vs. 6 weeks, 7.3 vs. 7.6 weeks, 3 
vs. 7 weeks, confirmed by site vs. recorded in 
the database, respectively).
Safety was assessed using adverse events 
(AEs) and serious adverse events (SAEs), re-
corded from the first injection through week-
Figure 3. Patient disposition. aReceived ≥1 dose 
belimumab; bpatients included in the ITT popula-
tion for whom ≥1 post belimumab treatment PK 
sample was analyzed. AE = adverse event; ITT = 
intent-to-treat; PK = pharmacokinetic.
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12 exit visit, and changes in laboratory val-
ues. Pain was assessed using a visual analog 
scale (VAS; 0 – 100 mm) immediately after 
an injection and 1 and 24 hours post injec-
tion, a rating of 0 represented no pain, and 
100 worst possible pain.
Statistical analysis
No formal sample size calculation was 
conducted. The intent-to-treat (ITT) popula-
tion included all patients who received at least 
1 SC dose. For the primary and secondary 
endpoints, only patients who attempted self-
administration of the injection at all relevant 
time points were included. Patients who had 
at least 1 post-belimumab serum sample ana-
lyzed were included in the PK population. 
Continuous variables were summarized with 
the mean, median, standard deviation (SD), 
25th and 75th percentiles, minimum and maxi-
mum. Categorical variables were summarized 
with frequency counts and percentages.
Results
Patient population
95 patients enrolled, and 91 completed 
the study; 3 withdrew due to AEs, and 1 
was lost to follow-up (Figure 3). The ma-
jority was female (n = 88), white (n = 69), 
and mean (SD) age was 44.8 (12.50) years 
(range: 24 – 74 years). Mean (SD) weight 
was 85.9 (24.70) kg, and mean (SD) BMI 
was 31.4 (8.68) kg/m2. The majority of pa-
tients switched directly from belimumab IV 
(n = 93), and 2 patients switched directly 
from belimumab SC by prefilled syringe. 
Following the study, 90 patients resumed 
treatment with belimumab IV.
Median exposure was 56 days (range: 
14 – 60 days), and 91 patients (96%) at-
tempted 7 or 8 injections. Mean (SD) com-
pliance was 98% (5.15).
Successful self-administration
At weeks 1 and 2, 99% (89/90) of patients 
who attempted an injection successfully ad-
ministered belimumab using the autoinjector 
(Figure 4). At week 2, 5/95 patients (ITT) 
did not attempt an injection and so were ex-
cluded from primary endpoint analysis. At 
week 1, clinical staff assisted with the injec-
tion for 5 patients, and these were included as 
successful injections. At weeks 4 and 8, 98% 
(85/87) of patients who attempted an injection 
successfully self-administered belimumab. 
Patients reported success in similar propor-
tions at home and in the clinic; at home, 93% 
(81/87) of patients who attempted an injection 
successfully self-administered belimumab 
(weeks 3, 5, 6, and 7). Overall, 5 patients 
failed a first attempt but completed a second 
successful injection (1 each at weeks 1, 3, and 
5, and 2 at week 7).
Pharmacokinetics
Median serum belimumab trough con-
centration at week 8 was 113 µg/mL (range: 
Figure 4. Percentage of successful injections at 
each week. Data missing for 5 patients at weeks 1 
and 2, and for 8 patients at weeks 3 – 8. Data la-
bels represent number of patients.
Figure 5. Median belimumab serum concentra-
tion by week (PK population). Minimum and maxi-
mum values: week 1 (0, 504.29 µg/mL), week 2 
(17.47, 467.86 µg/mL), week 4 (34.41, 278.27 µg/
mL), week 8 (30.19, 296.47 µg/mL). Dashed line: 
lower limit of quantification (0.1 µg/mL). PK = phar-
macokinetic.
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30 – 296 µg/mL) (Figure 5). Following the 
switch from IV to SC, steady-state trough 
belimumab levels were attained on average 
by week 2 (Figure 5). When switching from 
IV to SC administration, median percentage 
changes in belimumab concentration be-
tween week 8 and week 1 were –51%, –23%, 
1%, and –3% for patients with intervals of 
≤ 1.5 weeks, 1.5 – 2.5 weeks, 2.5 – 3.5 weeks, 
and > 3.5 weeks, respectively (Figure 6).
The difference between week 8 and week 
1 belimumab concentrations was greater for 
patients with a normal BMI (BMI 18.5 to 
< 25; + 14% median) compared with patients 
classified as overweight (BMI 25 to < 30; 
+ 6% median) and obese (BMI ≥ 30; –34% 
median).
Injection failures
Overall, 98% (720/736) of attempted in-
jections were successful. Of the unsuccess-
ful injections, 12 were associated with use 
errors only, 2 were associated with device 
errors only, and 2 were initially recorded as 
both a use error and device error, but after 
follow-up with the clinical site, they were at-
tributed to use errors only (Table 1). Four of 
the use errors were attributed to one patient 
and none of the other patients repeated a use 
error. There were 2 reported device malfunc-
tions, 1 of which was substantiated as an ac-
tual device error.
Patient diaries
Across 8 weeks, 4 patients required as-
sistance or further training to complete their 
injection successfully; this was in addition 
to the 5 patients who required assistance at 
week 1, as noted above. The percentage of 
patients who used the provided instructions 
generally decreased over time from 94% 
(89/95 patients) at week 1 to 71% (65/91 
patients) at week 8. Use of injection site lo-
cations (left thigh, right thigh, left abdomen, 
right abdomen) was balanced. The majority 
of patients agreed that the autoinjector was 
Figure 6. Effect of the IV-to-SC interval on week-8 
to week-1 concentration difference (PK populationa). 
aExcludes two patients who received belimumab SC 
via prefilled syringe at study entry. Boxes represent 
the median, 25th and 75th percentiles. Ends of whis-
kers represent the maximum observation below the 
upper fence (75th percentile + 1.5 × interquartile 
range) and the minimum observation above the 
lower fence (25th percentile – 1.5 × interquartile 
range). Crosses (+) represent the mean. Circles 
with a cross (X) represent outliers. IV = intravenous; 
PK = pharmacokinetic; SC = subcutaneous.
Table 1. Summary of administration errors.
Wk 1 
(n = 96)a
Wk 2 
(n = 90)a
Wk 3 
(n = 94)a
Wk 4 
(n = 88)a
Wk 5 
(n = 91)a
Wk 6 
(n = 93)a
Wk 7 
(n = 92)a
Wk 8 
(n = 92)a
Use errors, n (%)
 Any use error 1 (1) 1 (1) 2 (2) 1 (1) 1 (1) 3 (3) 4 (4) 1 (1)
 Autoinjector not properly activated on injection site 1 (1)b 0 0 0 0 0 0 0
 Autoinjector pulled away before end of injection 0 1 (1) 1 (1)b 0 1 (1) 1 (1) 1 (1)b 1 (1)
 Medication observed at the injection site 0 0 1 (1) 1 (1) 0 2 (2) 3 (3) 0
Device error, n (%)
 Any device error 0 0 0 0 1 (1) 1 (1) 2 (2) 0
 Delivery stopped before end of injection 0 0 0 0 1 (1)b 0 0 0
 Autoinjector did not activate 0 0 0 0 0 0 1 (1)b 0
 Autoinjector leaked 0 0 0 0 0 1 (1)c 1 (1)c 0
aNumber of injection attempts. In 5 cases, a patient had 2 attempts to administer their dose; bthe first attempt at injection was unsuccess-
ful, the second attempt was successful; c1 patient reported unsuccessful injections at week 6 and 7, which were initially attributed to both 
use error and device error; further investigation determined that the injections were unsuccessful due to use error only.
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comfortable to hold (≥ 98%) and that injec-
tion time was acceptable (≥ 97%).
Safety
Overall, 39 (41%) patients reported at 
least 1 treatment-emergent AE, and 15 (16%) 
were considered drug-related (Table 2). Four 
(4%) patients reported 7 SAEs; 4 occurred in 
1 patient (anemia, neutropenia, pneumonia, 
pyrexia), and there was 1 case each of post-
operative abscess (drug withdrawn), pulmo-
nary embolism, and deep vein thrombosis. 
Three (3%) patients reported 5 AEs leading 
to discontinuation (nausea, vomiting, and 
pyrexia in 1 patient, and 1 case each of her-
pes zoster and postoperative abscess). Two 
nonopportunistic infections (herpes zoster) 
were reported, and 4 postinjection nonseri-
ous systemic reactions via broad customized 
medical dictionary for regulatory activi-
ties query (CMQ; cough, pruritus, rash, and 
swelling). Two severe AEs were reported (1 
case each of postoperative abscess and deep 
vein thrombosis). No deaths occurred.
Injection site reaction AEs were reported 
by 4 (4%) patients; none were serious or re-
sulted in study discontinuation. Mean injec-
tion site pain (according to the 0 – 100 mm 
VAS) at dosing was highest with the second 
injection (8.15 mm) and reduced with re-
peated administrations (2.30 mm at week 8). 
Pain levels reduced 1 hour after dosing and 
ranged from 0.12 to 1.08 (Table 3). Most pa-
tients rated their injection pain as acceptable. 
Sharp stinging pain was reported most fre-
quently, followed by burning pain (data not 
shown).
Discussion
This was the first study conducted in 
patients with SLE to assess use of a novel 
autoinjector for self-administration of belim-
umab SC. PK of the switch from belimumab 
IV to belimumab SC were examined.
The majority of patients was able to suc-
cessfully self-administer belimumab using 
the autoinjector, both at home and in the clin-
ic. A small number of patients had assistance 
during their first injection in the clinic or 
required a second attempt. This is not unex-
pected in patients who may be self-adminis-
tering an injection for the first time, as initial 
anxiety with self-injection has been reported 
previously in patients with RA [19]. In clini-
cal practice, patients would likely receive 
support from their healthcare practitioner for 
first administrations, and therefore the study 
represents real-world clinical practice.
Table 2. Summary of adverse events.
AEs, n Patients, n (%)
N = 95
Any AEa 105 39 (41)
 Infections and infestations 27 18 (19)
 Musculoskeletal and connective tissue disorders 20 12 (13)
 General disorders and administration-site conditions 17 10 (11)
Drug-related AEb 25 15 (16)
 General disorders and administration site conditions 10 6 (6)
 Infections and infestations 9 6 (6)
 Serious AE 7 4 (4)
Severe AE 2 2 (2)
AEs leading to discontinuation 5 3 (3)
Fatal AE 0 0
aThose occurring in > 10% are listed; bthose occurring in > 5% are listed (listed 
as system organ class). AE = adverse event; SAE = serious adverse event.
Table 3. Injection site pain.
Week Time point Mean VAS score  
(0 – 100 mm scale)
Acceptable, n (%)
Yes No
Week 1 Dose 7.93 61 (65) 1 (1)
1 hour 0.40 10 (11) 1 (1)
24 hours 0.06 4 (5) 0
Week 2 Dose 8.15 44 (51) 2 (2)
1 hour 0.74 9 (11) 0
24 hours 0.36 3 (4) 0
Week 3 Dose 6.46 50 (56) 2 (2)
1 hour 0.51 9 (10) 0
24 hours 0.06 2 (2) 0
Week 4 Dose 4.08 35 (41) 1 (1)
1 hour 0.21 4 (5) 0
24 hours 0.01 1 (1) 0
Week 5 Dose 4.38 37 (41) 2 (2)
1 hour 1.08 7 (8) 0
24 hours 0.03 3 (3) 0
Week 6 Dose 3.28 35 (38) 3 (3)
1 hour 0.12 4 (4) 0
24 hours 0.02 2 (2) 0
Week 7 Dose 3.67 36 (40) 1 (1)
1 hour 0.20 4 (4) 0
24 hours 0.11 2 (2) 0
Week 8 Dose 2.30 28 (31) 1 (1)
1 hour 0.31 2 (2) 0
24 hours 0.18 2 (2) 0
VAS = visual analog scale.
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With the targeted IV-to-SC switching 
interval of 1 to 4 weeks, patients’ belim-
umab concentrations reached steady-state 
concentration by week 2. For patients with 
a switch interval of more than 2.5 weeks 
between doses, the week-8 to week-1 differ-
ence in trough concentrations was close to 
zero. Patients with a switch interval of ≤ 2.5 
weeks had a week-1 belimumab concentra-
tion higher than their week-8 steady-state 
concentration. This is not a safety concern as 
the median concentration before the first SC 
dose in the present study, where a minimum 
switching interval of 1 week was imposed, 
was substantially lower than the maximal 
belimumab concentration that is typically 
observed immediately after the last IV dose 
(313 µg/mL) [5]. Therefore, the PK results 
from this study support a 1 – 4-week inter-
val for switching between belimumab IV 
and belimumab SC. In addition, the stable 
transition from IV to SC dosing demonstrat-
ed here supports the use of the prefilled sy-
ringe for administration of belimumab SC as 
bioequivalent exposures have been demon-
strated for belimumab SC administration us-
ing the autoinjector and the prefilled syringe 
[15]. The 200-mg dose was selected based on 
previous analyses that showed that weekly 
belimumab 200 mg SC would achieve simi-
lar steady-state belimumab exposures to that 
of monthly belimumab 10 mg/kg IV [16]. 
The present results support this dose selec-
tion; the median concentration of 113 µg/
mL is consistent with the simulated steady-
state concentrations for weekly belimumab 
200 mg (104 µg/mL) and monthly belimum-
ab 10 mg/kg IV (110 µg/mL) [20]. Weekly 
SC dosing may be advantageous in terms of 
PK as fluctuations in steady-state concentra-
tions are reduced compared with monthly IV 
administration due to more frequent dosing 
and slow SC absorption [20].
Patients with active SLE demonstrated 
a good level of usability and reliability with 
the autoinjector, confirming results of a pre-
vious study conducted in healthy subjects 
[15]. The majority of injection failures was 
due to user error, which were rectified with 
additional training and slight adjustments in 
user instructions. It was important that pa-
tients were comfortable and confident with 
the device, and when choosing between an 
SC or IV regimen (assuming comparable ef-
ficacy and safety profiles), patient preference 
and pharmacoeconomics should be taken 
into account [21]. The availability of an al-
ternative formulation to belimumab IV will 
give patients the option to self-administer at 
home, avoiding the need to attend the infu-
sion clinic every month. SC administration 
may have additional advantages, such as im-
proved accessibility for patients with poor 
IV access and increased compliance and re-
duced costs, when clinic costs, travel expens-
es, and missing days from work or childcare 
are considered. In a claims database study 
in RA, patients who initiated treatment with 
SC biologics were significantly more likely 
to meet the criteria for high adherence com-
pared with those who initiated treatment 
with IV biologics [22]. Costs were also lower 
for SC biologics, although it should be noted 
that these were not direct comparisons using 
the same biologic. Such comparisons of ad-
herence and costs are not currently available 
in SLE.
The safety data reported here are con-
sistent with the known safety profile of be-
limumab IV, and there was a low incidence 
of SAEs. These safety data from 95 patients 
also support a switch from IV to SC admin-
istration. Injection-site pain must be con-
sidered when using SC medications, as this 
affects the patient’s overall experience [23] 
and willingness to continue. Here, in patients 
with SLE, pain levels were low, short-lived, 
and declined with repeated administration, 
as patients gained experience with the device 
and procedure.
Our study objectives and patient popula-
tion warranted an open-label design, which, 
along with the relatively short treatment du-
ration, may be considered a limitation. Simi-
larly, there may be some variability across 
the population and in the self-reported results 
from patient diaries, which assessed home 
use. However, the good level of usability and 
reliability demonstrated, directly assessed by 
the clinic site staff, is consistent with the self-
reported home data. Efficacy was not exam-
ined, and biomarker data were not collected; 
efficacy of belimumab SC will be reported in 
a phase-3 randomized trial [24].
In conclusion, a novel autoinjector de-
vice had a good level of reliability and us-
ability for self-administration of belimumab 
SC in patients with SLE and was well toler-
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ated. PK data strongly support a time interval 
of 1 – 4 weeks, when switching between the 
IV and SC administration.
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